National socioeconomic status influences disease severity at treatment start and duration of treatment in patients with psoriatic arthritis and axial spondyloarthritis - EurekAlert!
Psoriatic arthritis: Hit hard and early - EurekAlert!
Approval of bimekizumab in the United States, an IL-17 A and F blocker with European approval for psoriatic arthritis. Dermatologists now have a range of choices for highly effective and safer options, both in biologics and orals.
